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Review
Structural brain characteristics in
treatment-resistant depression: review
of magnetic resonance imaging studies
Margit Philomène C. Klok, Philip. F. van Eijndhoven, Miklos Argyelan, Aart H. Schene and Indira Tendolkar
Background
Major depressive disorder (MDD) has been related to structural
brain characteristics that are correlated with the severity of dis-
ease. However, the correlation of these structural changes is less
well clarified in treatment-resistant depression (TRD).
Aims
To summarise the existing literature on structural brain charac-
teristics in TRD to create an overview of known abnormalities of
the brain in patients with MDD, to form hypotheses about the
absence or existence of a common pathophysiology of MDD and
TRD.
Method
A systematic search of PubMed and the Cochrane Library for
studies published between 1998 and August of 2016 investigat-
ing structural brain changes in patients with TRD compared with
healthy controls or patients with MDD.
Results
Fourteen articles are included in this review. Lower grey matter
volume (GMV) in the anterior cingulate cortex, right cerebellum,
caudate nucleus, superior/medial frontal gyrus and hippocam-
pus does not seem to differentiate TRD from milder forms of
MDD. However, lower GMV in the putamen, inferior frontal gyrus,
precentral gyrus, angular- and post-central gyri together with
specific mainly parietal white matter tract changes seem to be
more specific structural characteristics of TRD.
Conclusions
The currently available data on structural brain changes in
patients with TRD compared with milder forms of MDD and
healthy controls cannot sufficiently distinguish between a
‘shared continuum hypothesis’ and a ‘different entity hypoth-
esis’. Our review clearly suggests that although there is some
overlap in affected brain regions between milder forms of MDD
and TRD, TRD also comes with specific alterations in mainly the
putamen and parietal white matter tracts.
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Major depressive disorder (MDD) is the most common psychiatric
disorder with a lifetime prevalence estimate of 9.4%.1 Although two-
thirds of patients with MDD recover with current treatment
approaches, the condition in one-third has a treatment-refractory
course. When treatment does not result in remission, it is an unsuc-
cessful trial, whether because of a lack of efficacy (i.e. lack of remis-
sion) or intolerable side-effects. The degree of treatment resistance
is gauged by the number of treatment steps needed to achieve an
adequate benefit.2 Treatment-resistant depression (TRD) is asso-
ciated with prolonged, costly in-patient periods of treatment.3 The
extent to which individuals with TRD versus treatment-responsive
MDD differ in terms of aetiology or pathophysiology remains
mostly obscure. Early-life stress is hypothesised to increase treat-
ment resistance4 and individuals with TRD may exhibit differences
in brain circuit function5 but nevertheless the underlying mechan-
isms of therapy resistance are not yet know;6 these demand new
insights regarding the underlying pathophysiology and for treat-
ment approaches. Advances in neuroimaging techniques may
allow us to identify structural differences in grey matter in MDD
and relate it to the severity of disease.
Structural characteristics in MDD
Koolschijn and colleagues7 were the first to conduct a meta-
analysis on regions of interest (ROIs) extracted from six studies
including a total of 2418 patients with MDD and 1974 healthy indi-
viduals. Patients showed significant volume reductions in frontal
regions, in particular in the anterior cingulate cortex (ACC) and
the prefrontal cortex, most pronounced in the orbitofrontal
cortex. The hippocampus, the putamen and caudate nucleus
showed moderate volume reductions. The authors concluded that
MDD is associated with structural brain abnormalities, particularly
in those brain areas involved in emotion processing and stress regu-
lation. To account for potential confounding because of different
methods Bora and colleagues8 conducted the first coordinate-
based meta-analysis of voxel-based morphometry (VBM) studies
in MDD. They included 23 studies with a total of 986 patients
with MDD and 937 healthy controls. The authors could confirm a
significant reduction in GMV in the ACC and in the dorsolateral
and dorsomedial prefrontal cortex and conclude that grey matter
reduction in rostral ACC is the most consistent finding in VBM
studies of MDD. Arnone et al9 used a novel voxel-based technique
based on the statistical parametric maps from individual magnetic
resonance imaging (MRI) studies, including a total of 472 patients
with MDD and 680 healthy controls. They could confirm the
above-mentioned GMV reductions in patients with MDD in key
brain regions implicated in emotion generation and regulation
including diffuse bilateral GMV loss in ventrolateral and ventro-
medial frontal systems extending into the temporal gyri.
Moreover, the authors detected GMV reduction in the right para-
hippocampal and fusiform gyri, hippocampus and bilateral thal-
amus, parietal lobes and cerebellum in MDD. Schmaal et al10
performed the largest ever worldwide study by the ENIGMA
MDD Working Group on cortical structural alterations in MDD
and analysed MRI scans from 2148 patients with MDD and 7957
healthy controls. They also could confirm cortical grey matter loss
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in the orbitofrontal cortex, anterior and posterior cingulate, insula
and temporal lobes. They describe that these effects were more pro-
nounced in the first-episode and adult-onset groups of participants
with MDD. Compared with matched controls, the patients with
MDD were found to have lower total surface area and regional
reductions in frontal regions including the medial orbitofrontal
cortex (OFC) and superior frontal gyrus, and primary and higher
order visual, somatosensory and motor areas.
Wise et al11 investigated whether volumetric changes in MDD
can be differentiated from those in bipolar disorder. They computed
a meta-analysis of VBM studies of 50 data-sets including 1736 indi-
viduals with MDD and 2365 healthy controls, and 36 data-sets
including 980 individuals with bipolar disorder and 1427 healthy
controls. They describe smaller GMV in individuals with MDD in
clusters in the dorsomedial and ventromedial prefrontal cortex,
including the ACC and bilateral insula in both MDD and bipolar
disorder. They also found smaller GMV in the right dorsolateral
prefrontal cortex and left hippocampus, along with cerebellar, tem-
poral and parietal regions that were more substantial in MDD when
compared with bipolar disorder as well as healthy controls.
Structural connectivity analyses using diffusion tensor imaging
(DTI) techniques provides complementary information on these
regional reductions in grey matter and allow us to investigate the
connectivity between frontal and subcortical structures.12
Fractional anisotropy measures how inhomogeneous (anisotropic)
the diffusion is in all directions and is commonly used because of
its sensitivity to microstructural change, such as altered myelinisa-
tion,13 although fractional anisotropy is less specific with regard
to the type of change.14,15 Liao and colleagues16 performed an
initial meta-analysis of DTI data on a sample of 231 patients with
MDD and 261 comparison participants. Despite heterogeneous
imaging techniques, decreased fractional anisotropy in the white
matter fascicles connecting the prefrontal cortex with cortical
(frontal, temporal and occipital lobes) and subcortical areas (amyg-
dala and hippocampus) seems to be a common abnormality in
MDD.
Wise et al17 investigated white matter microstructure differ-
ences and similarities between MDD and bipolar disorder by com-
paring fractional anisotropy between patients and controls. They
identified white matter abnormalities in 736 patients with MDD
versus 668 controls and 536 patients with bipolar disorder versus
489 controls. They found a significant decrease in fractional anisot-
ropy in the genu of the corpus callosum in both MDD and bipolar
disorder and relate these changes to the function of this structure in
connecting the two hemispheres of the prefrontal cortex and its role
in mood regulation.
All of the above-mentioned studies focused onMDD in general,
but relatively little is known about the structural characteristics of
TRD. It remains unclear if the underlying brain changes in TRD
are simply a more quantitatively severe variant of MDD or
whether TRD shows a distinctive pattern of structural brain charac-
teristics, corresponding to different pathophysiology with specific
biomarkers and different targets for treatment.
Following the absence of a uniform definition of treatment
resistance, the lack of a consistent valid quantification model has
been one of the major causes of inconsistency not only affecting
the clinical setting but also affecting the research area. Multiple
methods for defining and determining treatment resistance have
been used ever since the introduction of the concept of TRD in
1974.18 At present, the diagnosis of TRD is merely defined by the
responsiveness to antidepressants, clinical signs and symptoms.
Although the Thase and Rush staging model is commonly used to
determine the level of treatment resistance in depression,19 it does
not integrate potential pathophysiological features of TRD.20 In
the light of these open questions, we set out to review the current
literature on structural brain characteristics of patients with TRD
in comparison with both healthy controls and to patients with
milder forms of MDD in an attempt to identify potential quantita-
tive and qualitative structural brain abnormalities characterising
TRD.
Method
Search strategy
We performed a literature search in the databases of PubMed and
Cochrane Library. Key words used were: “major depressive dis-
order”, “treatment-resistant”, “treatment-refractory” and “MRI”.
This first search yielded 115 articles. Manual search with biblio-
graphic cross-referencing yielded ten more articles. Two authors
(M.P.C.K./P.v.E.) reviewed all 125 abstracts. For inclusion in this
review we formulated the following criteria: number of patients
≥15; structural brain characteristics investigated using MRI.
Structural imaging analyses included ROI analyses or VBM.
Moreover, we included DTI or magnetisation transfer imaging
(MTI) as other forms of structural imaging. Studies had to
include patients with TRD, where TRD was defined by a Thase
and Rush stage of ≥II (failure of at least two adequate trials of at
least two distinctly different classes of antidepressant medications
for at least 6 weeks);19 articles that did not use the Thase and
Rush model were only included if they met a comparable minimal
level of treatment resistance; the investigated patients were at least
compared with healthy controls, but ideally to both healthy controls
and patients withMDD. In total, 33 articles met inclusion criteria on
the basis of the abstract and were subsequently reviewed in more
detail by two authors (M.P.C.K./P.v.E.). Out of those, another 19
articles did not meet inclusion criteria and 14 articles were system-
atically reviewed. For an overview of the selection process see Fig. 1.
Construction of this review
Wewill review the results based onMRImethodology (grey or white
matter; VBM, MTI, automatic or manual volumetry) and type of
analysis (whole brain versus ROI). Results will be weighted as to
whether they reflect whole-brain analyses or ROI analyses, which
provides results that are not as comprehensive.
Results
Characteristics of the studies included in this review
Characteristics of the included studies are listed in Table 1. The
median number of patients included in the studies was 24.5
(range 15–115). The mean age of patients included in the studies
was 39.9 years (range 26.8–52.1). The male/female ratio of patients
included in the studies shows an overall dominance for female
patients (8/14 studies) in line with the gender-specific prevalence
of MDD. Note that gender was used as covariate in some but not
all studies. Twelve studies fulfilled Thase and Rush stage ≥II. Two
studies included patients with non-responsiveness to at least two
courses of antidepressant medications for at least 4 weeks. The
latter did not specify the classes of antidepressant and so did not
automatically fulfil Thase and Rush stage II or ≥II.
Four of those 14 studies allowed us to look into dissociating and
overlapping structural changes of different stages of major depres-
sion by comparing TRD not only to matched healthy controls but
also to milder forms of major depression as defined by level of treat-
ment resistance. Two of these four studies compared patients with
TRD with healthy controls, patients with first-episode depression
and patients with remitted–recurrent depression (see Table 1).
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Fig. 1 Flow diagram for inclusion in the review.
TRD, treatment-resistant depression; MDD, major depressive disorder.
Table 1 Characteristics of included studies
Author (Year) n Method Age, years (range or s.d.a) Male/femaleb Control group (n) Level of therapy resistance
Phillips et al (2015)29 26 ROI 46 (18–65) 8/18 HC (28) T&R ≥II
Sun et al (2009)34 45 ROI 40.8 (18–63) 22/23b HC (30) T&R ≥II
Furtado et al (2008)33 45 ROI 37.5 (18–62) 22/23b HC (30) T&R ≥II
Lan et al (2016)24 27 WB-VBM 41.5 (16) 9/18b HC (27) T&R ≥II
Machino et al (2014)26 29 WB-VBM 39.6 (8.3) 16/13b HC (29) T&R ≥II
Serra-Blasco et al (2013)23 22 WB-VBM 49 (8) 4/18 HC/FED/RRD (22/22/22) T&R ≥III
Zhang et al (2009)27 15 MTI 33.5 (18–51) 10/5 HC (15) T&R ≥II
Shah et al (2002)22 20 WB-VBM 48.9 (9.8) 13/7 HC/RfD (20/20) T&R ≥IIIc
Ma et al (2012)21 18 WB-VBM 27.4 (7.74) 11/7 HC/DRT (17/17) T&R ≥II
Young et al (2016)30 22 WB-VBM 52.1 (33.9–68) 8/14 HC (21) T&R ≥IV
Guo et al (2012)20 23 DTI 27.4 (7.74) 11/12 HC (19) T&R ≥II
Peng et al (2013)36 30 DTI 26.9 (5.28) 19/11 HC (25) T&R ≥IIIc
de Diego-Adelino et al (2013)37 18 DTI 48.5 (7.3) 3/15 HC/FED/RRD (17/19/15) T&R ≥II
Maller et al (2012 and 2013)31,32 115 ROI 39.6 (29–62) 61/54 HC (86) T&R ≥II
ROI, region of interest; HC, healthy control; T&R, Thase and Rush stagingmodel:≥II, non-responsiveness to at least two courses of antidepressant medications for at least 6 weeks;≥III, stage
II resistance plus failure of an adequate trial of tricyclic antidepressant; ≥IV, stage III resistance plus failure of an adequate trial of a monoamine oxidase inhibitors; WB-VBM, whole-brain
voxel-based morphometry; FED, first-episode depression; RRD, remitted–recurrent depression; MTI, magnetisation transfer imaging; RfD, recovered from depression; DRT, depression
responsive to treatment; DTI, diffusion tensor imaging.
a. Range or s.d. depending on the source of information.
b. Gender included as covariate.
c. Non-responsiveness to at least two courses of antidepressant medications for at least 4 weeks.
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One study compared patients with TRD to patients recovered from
depression and one study compared patients with TRD with
patients with recurrent depression responding to treatment.
Results of individual studies.
Results of the individual studies have been summarised in supple-
mentary Tables 1 and 2; available online at: https://doi.org/10.
1192/bjo.2019.58) whereby we also relate the individual findings
to the known meta-analyses of MDD.
Grey matter studies
Whole-brain VBM studies
An important issue to address in this section regarding the individ-
ual studies is the issue of statistical inference. Considering the rather
small sample sizes of the included studies, the risk of type I errors
because of the lack of appropriate control for multiple comparisons
is highly likely. Given this, we include the method of correction for
multiple comparisons in the separate studies.
Studies that included an MDD control group without TRD. Ma
et al21 investigated 18 patients with TRD and compared them with
17 patients with first-episode MDD as well as 17 healthy controls.
They used Alphasim (permutation-testint) to correct for multiple
comparisons (P < 0.005), but applied a looser threshold for the
caudate nucleus (P < 0.01). Regions with abnormal GMV were also
used as seed regions for functional connectivity analyses. In compari-
son with controls, patients with TRD showed decreased GMV in the
right middle temporal cortex and the bilateral caudate, but only the
latter was specific for TRD, while volume decreases in the middle
temporal cortex were also present in the first-episode MDD group.
Moreover, the GMV decrease in the right middle temporal cortex
correlated with the duration of illness across all patients with
MDD. The decrease in caudate volume in patients with TRD was
associated with altered caudate–prefrontal connectivity, which may
indicate a substrate for dysregulation of reward mechanisms.
Shah et al22 compared 20 patients with TRD with 20 patients
who were recovered from recurrent MDD (Hamilton Rating Scale
for Depression ≤5) and 20 healthy controls. Results were corrected
for multiple comparison by means of the cluster-wise correction
implemented in SPM. They found reduced grey matter density in
the right superior frontal gyrus and the right putamen in the TRD
group compared with the combined control and recovered
groups. Complementary manual volumetry (not corrected for mul-
tiple comparisons) indicated reduced volume of the right prefrontal
lobe and the right caudate nucleus (TRD versus non-TRD group,
P = 0.04; TRD versus control group, P = 0.048), which contributed
to the pattern of frontostriatal atrophy in TRD that appeared
to be more pronounced in more severe illness. In addition, the
VBM analysis detected changes in tissue composition in the
hippocampus and rostral ACC selectively in the patients with TRD.
Serra-Blasco and colleagues23 investigated a group of 22 patients
with TRD and compared them with both healthy controls (n = 32)
and patients with MDD (first-episode depression, n = 22 and
remitted–recurrent depression, n = 22). Results were familywise-
error (FWE)-corrected at P < 0.05 in SPM. Compared with
healthy controls, the patients with TRD showed a broad set of clus-
ters of reduced GMV in the anterior cingulate gyrus, superior,
medial and inferior frontal gyri, the insula, the parahippocampal
gyrus and the transverse temporal gyrus (FWE-corrected at
P < 0.05; threshold: 100 voxels). Except for smaller GMV in the
medial frontal gyrus, the patients with TRD revealed qualitative
GMV changes compared with the first-episode group in the precen-
tral gyrus, the medial frontal gyrus, the insula, the transverse
temporal gyrus, the inferior parietal lobule and the posterior cingu-
late. In subsequent analyses using the automated segmentation
program FreeSurfer the TRD group revealed smaller volumes of
the right medial frontal gyrus and the left insula in comparison
with those in the first-episode group. Again, these changes corre-
lated with illness duration.
Studies that only included a healthy control group. Lan et al24
investigated 27 patients with TRD with a current major depressive
episode and compared them with 27 healthy controls. Results were
FWE-corrected (P < 0.05, cluster threshold 500 voxels) in SPM.
They found six clusters of decreased GMV in the TRD group
(FWE-corrected at P < 0.05; threshold: 500 voxels). These clusters
were located in the left medial prefrontal cortex, including the
ACC, the left lingual gyrus, the left middle and superior temporal
gyrus, the left insula, the posterior lobe of the right cerebellum
and the right angular gyrus. Additionally, the TRD group were
treated with high-frequent repetitive transcranial magnetic stimula-
tion over the left dorsolateral prefrontal cortex over 5 weeks, which
resulted in a response in 33% of the patients. Post-treatment
imaging showed that four of the clusters (the left ACC, the left
insula, the left superior temporal gyrus and the right angular
gyrus) showed selective GMV increase after transcranial magnetic
stimulation treatment. In addition, grey matter increase of the
ACC correlated with clinical improvement. These findings are in
line with state-related neuroplasticity changes that are also reported
in non-TRD forms of depression.25
Machino et al26 investigated 29 patients with TRD in compari-
son with healthy controls and found significantly smaller GMV in
ventral and dorsal parts of the ACC, the cerebellum and in the
right superior frontal gyrus. These results were not corrected for
multiple comparison (statistical threshold: P uncorrected < 0.001;
cluster: 50 voxels). Moreover, Lan et al24and Machino et al26
described reduced GMV in the right cerebellum in TRD compared
with healthy controls.
In summary, VBM studies reveal quantitative differences
between patients with TRD and with milder forms of MDD and
HCs in various fronto-temporolimbic regions as summarised in
supplementary Tables 1 and 2. A selective structural deficit in
TRD compared with other forms of MDD has been found in the
superior frontal gyrus, the middle and inferior temporal gyrus
and the caudate nucleus.
MTI
Zhang et al27 investigated 15 patients with clinically defined TRD
and 15 matched healthy controls combining MTI and standard
T1-weighted imaging for subsequent VBM analyses. MTI is a MRI
technique based on the selective saturation of protons bound to
macromolecules such as myelin thereby identifying damage to
myelin and to other cellular structures, such as the axonal mem-
branes.28 Surprisingly and possibly related to the low number of
participants, VBM revealed no morphological abnormalities in
the TRD group compared with the control group. However, a
reduced magnetisation transfer ratio was observed in the ACC,
insula, caudate tail and amygdala–parahippocampal areas.
ROI studies
The structures involved in TRD according to the ROI studies
reviewed are the amygdala, the hippocampus, the ACC, the entorh-
inal cortex and the corpus callosum. Phillips et al29 investigated
potential differences during an approximate 1-year follow-up
period in 26 patients with TRD compared with 28 matched
healthy controls in six ROIs (hippocampus, rostral middle frontal
gyrus, orbitofrontal cortex, rostral and caudal anterior cingulate
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cortices and inferior temporal gyrus). While surprisingly there were
no differences at baseline, after 1-year the non-remitting group
showed decreasing volume and cortical thinning over time in the
rostral middle frontal gyrus, orbitofrontal cortex and inferior tem-
poral gyrus, whereas the remitted group showed increasing
volume of thickness over follow-up in these regions.
Young et al30 combined grey and white ROI investigations in a
group of 22 patients with TRD and 21 healthy controls by combin-
ing VBM and tract based spatial statistics (TBSS) DTI. They focused
on frontolimbic structures and in particular targeted the amygdala,
hippocampus and ACC and connecting tracts. The VBM analysis
indicated that patients with TRD showed reduced GMVs relative
to healthy controls in the left medial OFC and bilateral hippocam-
pus with a particularly prominent cluster in the left hippocampus.
TBSS revealed elevated fractional anisotropy values in the left
angular bundle and right uncinate fasciculus.
Using manual segmentation of the hippocampus, Maller
et al31,32 investigated 115 patients with different stages of MDD
and concluded that particularly the tail section of the hippocampus
showed reduced volume in patients with TRD. Moreover, patients
with TRD had significantly more sulcal cavities and their presence
and length was associated with ageing.
As an important structure of the hippocampal formation Furtado
et al33 investigated the entorhinal cortex in 45 patients with TRD and
30 healthy age- and gender-matched controls. They found significant
reductions in the left entorhinal cortex only in female patients.
Sun et al34 investigated the morphology of subregions of the
corpus callosum in 45 patients with TRD compared with 30
healthy controls. Previous literature found larger total corpus callo-
sum and larger anterior and posterior quarters of the corpus callosum
in MDD (not specified as TRD).35 However, Sun and colleagues34
could not replicate those findings and only found reduced volume
of one part of the corpus callosum in the TRD group.
White matter: DTI studies (whole brain)
Guo et al20 investigated the white matter integrity in TRD and found
three brain white matter tracts with lower fractional anisotropy
compared with healthy controls. These tracts include the right
anterior limb of the internal capsule, the body of the corpus callo-
sum and bilateral external capsule. Despite the same methodology
Peng et al36 could not replicate the findings of Guo et al20 but
found reduced fractional anisotropy in the left limbic lobe uncus,
left middle frontal gyrus and right cerebellum posterior lobe in
patients with TRD compared with healthy controls.
Additionally, de Diego-Adelino et al37 found decreased frac-
tional anisotropy in patients with TRD compared with both
healthy controls and patients with first-episode depression.
Whole-brain analysis revealed a generalised significant reduction
in fractional anisotropy in TRD compared with healthy controls
mostly affecting bilateral inferior fronto-occipital fasciculus, bilat-
eral inferior longitudinal fasciculus, bilateral superior longitudinal
fasciculus, forceps major and forceps minor, the body of the
corpus callosum and bilateral cingulum. A significant decrease in
fractional anisotropy was also observed in patients with TRD com-
pared with patients with a first episode affecting the body of the
corpus callosum, bilateral superior longitudinal fasciculus, forceps
minor, forceps major, bilateral cingulum and bilateral inferior lon-
gitudinal fasciculus.
Discussion
To the best of our knowledge this is the first review of structural
brain changes in TRD both in comparison with healthy controls
and with non-TRD groups with MDD. Considering the results,
some methodological limitations have to be taken into account.
Sample sizes of the included studies were often small, limiting stat-
istical inference of the results. As a consequence, described struc-
tural differences in TRD may be the result of noise instead of real
differences. In most studies patients with TRD were only compared
with healthy controls but no other MDD groups (first-episode,
remitted–recurrent depression). This latter issue is crucial in the dif-
ferentiation of TRD fromMDD to understand whether TRD repre-
sents a continuum from less severe forms ofMDDor possibly comes
with its own structural brain characteristics. Although the compari-
son between patients with TRD and non-TRD groups of MDD
should address the aforementioned issues, we cannot rule out that
the patients with TRD were also characterised by longer duration
of depression and possibly affected by a larger allostatic load and
larger exposure to medication with possible neurobiological
effects. There was only one study that correlated measures of treat-
ment resistance (medication load) and duration with structural
changes.23
Below we will discuss the relevant findings per region. For the
purpose of this review we regard the studies that compared TRD
with a non-TRD control group as having the highest level of
evidence. Moreover, we focus our interpretation of results on con-
verging evidence from separate studies that identified the same
structures or converging evidence from different MRI modalities.
Converging evidence
From the studies that used a MDD control group, two out of three
studies identified decreased volume of the caudate nucleus.21,22
Based on these results the pattern of frontostriatal atrophy seems
to be the most discriminative aspect of TRD versus milder forms
of MDD. Hence, Wise et al,11 describe decreased GMV in the
caudate nucleus in MDD when compared with healthy controls as
well. On the one hand, this finding may illustrate the fact that
GMV loss in the caudate nucleus is not discriminating TRD from
MDD as it is seen in both groups. On the other hand, these findings
may illustrate a continuum of disease-related structural changes
starting at MDD and progressing to TRD as the GMV loss is
already present in MDD but is significantly greater in TRD when
compared with MDD, and hence could present a progression of
disease.
A decrease in insula volume was only found by Serra-Blasco
et al23 in comparison with a MDD group but it was also found in
comparison with healthy controls, so it may not be specifically
related to TRD.24 The level of treatment resistance was included
in this study in which they describe a negative correlated decrease
in the right medial frontal cortex and left insula. GMV loss in the
insula was also described in multiple meta-analyses investigating
MDD versus healthy controls,9–11 which again could reflect a pro-
gression of disease from MDD to TRD but does not support this
structure as being discriminative for TRD. Moreover, decreased
structural integrity of the corpus callosum was implicated in three
studies with different modalities,20,27,37 one of which included a
non-TRD control group.37 Wise et al,17 describe decreased frac-
tional anisotropy in the corpus callosum in MDD compared with
both healthy controls and patients with bipolar disorder. Whereas
Wise et al,17 do not include level of treatment resistance in their ana-
lysis it remains unclear whether the investigated group of patients
with MDD in their analysis perhaps also includes patients who
were treatment resistant as well, thereby possibly confounding
results with respect to our comparison.
In multiple studies that compared patients with TRD directly
with healthy controls, the ACC showed decreased GMV24,26,27
next to the cerebellum.24,26,36 These results are possibly not
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discriminative for TRD as these findings were not present in the
studies that compared patients with TRD- with a non-TRD MDD
group. Supporting evidence against the discriminative properties
of the ACC as well as the cerebellum for TRD are given by the
meta-analyses of Arnone et al,9 Wise et al11 and Schmaal et al,10
which describe these alterations in MDD as well. On the other
hand, surprisingly the basal ganglia volume loss21,22 was not
found when comparing TRD and healthy control groups, except
for the study by Zhang et al27 that found reduced MTR in the tail
of the caudate nucleus. This study also included duration of illness.
Two out of three ROI studies found reduced hippocampal
volume30–32 while most whole-brain studies failed to identify differ-
ences in hippocampal volume. In the remains of this discussion we
will take a closer look at the above-mentioned structures in order of
level of evidence from our review.
Basal ganglia
Decreased volume of the caudate nucleus seems to be specific to
TRD.10,21 Additional connectivity analysis of functional MRI data
by Ma et al,21 showed that this decrease in caudate nucleus
volume is accompanied by aberrant functional connectivity, both
increased and decreased, to frontal regions, which in turn often
show structural changes mainly as a function of illness severity.
This may support the hypothesis that TRD is characterised by fron-
tostriatal atrophy, which could be a neural correlate of deficient
reward mechanisms in TRD on top of other neurocognitive
mechanisms maintaining MDD. More supporting evidence comes
from the fact that the GMV of the putamen is not found to be sig-
nificantly decreased in MDD and thus the putamen may be a spe-
cific structure in the differentiation of TRD from MDD.
Medial prefrontal cortex
The medial prefrontal cortex is an important monitoring hub of the
prefrontal cortex that supports reward, decision-making and
memory functions.38 Given its broad cognitive functions in the
context of processing of emotional information, it is not surprising
that the medial prefrontal cortex plays a crucial role in the patho-
genesis of depression. Indeed our review supports the important
role of this region since volume decreases were found in two out
of three studies23,24 and were also apparent in the direct comparison
between TRD and first-episode depression.23 It may be relevant to
adjust the current neuropsychological testing of patients with
MDD such that medial prefrontal cortex function is more specific-
ally tested and could possibly be used for further diagnostics as well
as becoming more of a focus for treatment.
Medial and superior frontal gyrus
A decrease in volume of the medial and superior frontal gyri was
found in studies that used a non-TRD MDD group as well as
studies comparing TRD with healthy controls only.22,23,26
Although hypoactivity in these executive control regions is a
common finding in both MDD and TRD,9–11 Serra-Blasco et al23
showed a negative correlation between the volume of the medial
frontal gyrus and duration of illness. The evidence included in
this review does not give enough support to differentiate between
effect of chronicity over time and TRD-specific structural altera-
tions of these frontal regions.
Insula
In line with the aforementioned quantitative changes, smaller insula
volumes were found in the participants with TRD compared with
the first-episode MDD group23 and healthy controls24 that was
negatively correlated with duration of illness. The insula is involved
in the monitoring of internal states, and emotional and sensori-
motor processing, which is negatively affected in MDD.39
Interestingly, the insula is implicated by several studies as a correlate
of treatment response.40 Even in severe forms of TRD treated with
electroconvulsive therapy (ECT) increases in cortical thickness of
the insula was specific to responders.39
Corpus callosum
The role of the corpus callosum in MDD and TRD in particular
remains elusive since only ROI studies found decreased white
matter integrity in patients with TRD.20,27,37 Whereas Wu et al35
described larger total corpus callosum and larger anterior and pos-
terior quarters of the corpus callosum in MDD, Sun et al34 on the
contrary found reduced volume of the corpus callosum in one sub-
region in patients with TRD. Future studies should investigate
changes in the corpus callosum of patients with TRD compared
with other patients with MDD in whole-brain analyses taking
larger sample sizes also into account.
ACC
Our review once more supports the strong involvement of the ACC
in TRD andMDD in general as this structure by far reveals the most
consistent significant reduction in volume in TRD across multiple
studies (see supplementary Tables 1 and 2) in comparison with
healthy controls. Nevertheless, this structure is not specifically
affected in TRD as is shown by the loss of volume in non-TRD
groups of patients with MDD in the TRD studies as well as meta-
analyses investigating structural characteristics in MDD.9–11 Our
review supports the hypothesis that volume reduction of the ACC
already exists in the early course of depression8,23 and thus may
represent a stage-independent trait marker of the disease. Since
structural differences have even been found in vulnerable indivi-
duals volume reduction in ACC41 may even serve as a structural
endophenotype of depression but does not specifically characterise
TRD. Early structural changes to the ACC could indeed account for
aberrant functional connectivity of limbic–cortical pathways, which
has been proposed in several pathophysiological models of depres-
sion.42 Normal functioning of the rostral anterior cingulate, with its
direct connections to dorsal and ventral areas, is hence required for
reciprocal compensatory changes in depression.
Cerebellum
Where Lan et al24 and Machino et al26 not only agree on reduced
GMV in the ACC in TRD, they both show volume reduction of
the cerebellum, which was not, however, supported by Serra-
Blasco et al.23 However, loss of GMV of the cerebellum does not
seem to be specifically related to TRD as it is described in MDD
studies too.9,11 Transdiagnostic research has implied cerebellar
involvement in emotion regulation,43 and in line with this,
reduced GMV is common in attention-deficit hyperactivity disorder
as well. Cerebellar involvement in TRD does seem plausible, but
with affirmative literature still missing.
Hippocampus
Only the meta-analyses found smaller hippocampal volume among
patients with MDD7,44 suggesting that if there are TRD-specific
changes these are subtle and current studies are underpowered to
detect them. Shah et al22 suggest that a change in tissue composition
rather than volume characterises TRD in the hippocampus. Young
et al,30 showed that the hippocampus is altered by TRD only in com-
parison with healthy controls but strengthen their results by com-
bining the VBM method with a TBSS of the white matter, which
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revealed elevated fractional anisotropy values in the related fibre
tracts of the hippocampus (angular bundle and unicated fasciculus).
Maller et al31,32 hypothesise that the hippocampus tail may be
more sensitive to the pathophysiology of depression than other
parts of the hippocampus. They explain that in terms of structural
connections the posterior hippocampus projects to the dorsolateral
region of the prefrontal cortex, which is a well-known important
structure in TRD. Myelinated fibres enter and leave the posterior
hippocampus along the tail, which contains relatively few neuronal
elements compared with the body segment. The loss of GMV overall
could be too small to reach a level of significance and so would not
be detected in the standard measurements. It must be noted that
whole-brain analysis is a more comprehensive way to analyse differ-
ences, but it needs much higher effect sizes (given the same sample
size) to yield significant results, because of multiple comparison.
All together, even though the evidence given by the literature
included in this review about the involvement of the hippocampus
in TRD is not congruent, the hippocampus remains an important
structure for future research into TRD given also its potential role
in treatment effects of ECT in TRD.45
Superior longitudinal fasciculus
The superior longitudinal fasciculus is a big bundle of association
fibres that connects the dorsolateral prefrontal cortex and other
frontal regions with the temporal, parietal and occipital lobes. The
cingulum bundle lies within the cingulated gyrus and is an import-
ant association pathway linking prefrontal and parahippocampal
cortices. The inferior longitudinal fasciculus is an association fibre
tract that connects the occipital and temporal lobes, including the
hippocampus and amygdala.46 Whereas the superior longitudinal
fasciculus as well as the inferior longitudinal fasciculus are found
to have altered integrity in TRD by de Diego-Adelino et al,37
these structures are not described by themeta-analyses investigating
MDD9–11 and thus may be an interesting structure for future inves-
tigation of structural differences between MDD and TRD.
Implications and limitations
The main finding of this study is without a doubt the lack of conver-
gence. Even though occasional overlap is found there are no evident
converging structural changes in TRD that are replicated by differ-
ent research groups. Hypothetically this could be the result of the
small sample size of the individual studies leading to type I errors.
Given the need to learn more about the neural underpinnings of
TRD in comparison with MDD, it is important that large consortia
like ENIGMA focus on an investigation of these aspects.
An important limitation of this field of research is the lack of
agreement about the defining of patients with TRD. Criteria for
therapy resistance become more and more clarified these days. An
important issue to realise is the fact that the group of patients
which was used as a reference for MDD was determined before
TRD was considered to be a different group compared to MDD.
Most likely, the group of patients with MDD, as used in the MDD
studies, contained patients with TRD as well, and so this could
have biased the outcome of studies comparing these results with
patients with TRD.
Other potential confounders associated with TRD that have to
be taken into account are illness duration, age and history of medi-
cation use. Individuals with longer duration of illness could poten-
tially be more likely to run a treatment-resistant course. On the
other hand, one could hypothesise that if the duration of disease
continues, eventually every individual could potentially become
treatment resistant. The effects of age on the level of treatment
resistance would be very interesting to investigate as well as the
history of medication use. One could hypothesise that older age
and use of more medication could result in a more vulnerable
brain and so could influence the course of depression towards a
level of treatment resistance. To date, no relevant data about these
confounders are included in the literature and so could not be cor-
rected for. The fact that the reviewed articles did not control for
severity of depression in our opinion is a relevant issue to address.
Given the small sample size of the individual studies, one would
have to pool data for correction of severity, which might be an inter-
esting question for a future study.
Another difficulty in comparing results of research in this area is
the fact that multiple analysing techniques are used to map differ-
ences in brain structure during the course of depression. Most
important, the currently available data cannot sufficiently distin-
guish between a ‘shared continuum hypothesis’ and a ‘different
entity hypothesis’. Our review clearly suggests that although there
is some overlap in affected brain regions between milder forms of
MDD and TRD, TRD also comes with specific alterations mainly
in the putamen, inferior frontal gyrus, precentral gyrus, angular-
and post-central gyri together with specific mainly parietal white
matter tract changes.
The most legitimate way to investigate structural characteristics
in TRD would be to compare a group of patients with TRD with
patients with MDD who do not fulfil criteria for TRD, as well as
healthy controls. Moreover, to make a clear subdivision between
the different types of major depression, future research would
ideally want to including subgroups of patients with MDD with
first-episode depression versus remitted–recurrent depression and
compare both groups with a group with TRD; the putamen, inferior
frontal gyrus, precentral gyrus, angular- and post-central gyri
together with specific white matter tracts clearly serve as important
candidate regions.
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